| Home > Articles > Published articles > Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis |
| Date: | 2024 |
| Abstract: | Objective: Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) distinguish multiple sclerosis (MS) from MOG-associated disease in most cases. However, studies analyzing MOG-Ab at the time of a first demyelinating event suggestive of MS in adults are lacking. We aimed to (1) evaluate the prevalence of MOG-Ab in a first demyelinating event suggestive of MS and (2) compare clinical and paraclinical features between seropositive (MOG-Ab+) and seronegative (MOG-Ab-) patients. Methods: Six hundred thirty adult patients with available serum samples obtained within 6 months from the first event were included. MOG-Ab were analyzed using a live cell-based assay. Statistical analyses included parametric and nonparametric tests, logistic regression, and survival models. Results: MOG-Ab were positive in 17 of 630 (2. 7%). Fourteen out of 17 (82. 4%) MOG-Ab+ patients presented with optic neuritis (ON) compared to 227of 613 (37. 0%) MOG-Ab- patients (p = 0. 009). Cerebrospinal fluid-restricted oligoclonal bands (CSF-OBs) were found in 2 of 16 (12. 5%) MOG-Ab+ versus 371 of 601 (61. 7%) MOG-Ab- subjects (p < 0. 001). Baseline brain magnetic resonance imaging (MRI) was normal in 9 of 17 (52. 9%) MOG-Ab+ versus 153 of 585 (26. 2%) MOG-Ab- patients (p = 0. 029). Absence of CSF-OBs and ON at onset were independently associated with MOG-Ab positivity (odds ratio [OR] = 9. 03, 95% confidence interval [CI] = 2. 04-53. 6, p = 0. 009; and OR = 4. 17, 95% CI = 1. 15-19. 8, p = 0. 042, respectively). Of MOG-Ab+ patients, 22. 9% (95% CI = 0. 0-42. 7) compared to 67. 6% (95% CI = 63. 3-71. 3) of MOG-Ab- patients fulfilled McDonald 2017 criteria at 5 years (log-rank p = 0. 003). Interpretation: MOG-Ab are infrequent in adults with a first demyelinating event suggestive of MS. However, based on our results, we suggest to determine these antibodies in those patients with ON and absence of CSF-OBs, as long as the brain MRI is not suggestive of MS. ANN NEUROL 2024;95:116-128. |
| Grants: | Instituto de Salud Carlos III FI21/00282 Instituto de Salud Carlos III JR19/00007 Instituto de Salud Carlos III PI20/00800 |
| Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. |
| Language: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Published in: | Annals of neurology, Vol. 95, Núm. 1 (january 2024) , p. 116-128, ISSN 1531-8249 |
13 p, 950.8 KB |